SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Joe Frazier — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJoe Frazier
Date of birth1944-01-12
IdentifiersMRN HR-BX004-SYN-TD; SSN (made up) 000-04-5590
Document date2008-09-14
AuthorClarence Whitfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Seven-month review with the six-month liver cancer surveillance ultrasound and AFP. [S]

History of Present Illness

Mr. Frazier returns nine weeks after his preventive visit. He has taken semaglutide 1 mg weekly for four months, with metformin, lisinopril, amlodipine and atorvastatin, without missed doses or side effects. Home readings average 124/78. He has had no alcohol since March. He has lost 6.8 kg since intake. He had the six-month liver ultrasound this morning. His PSA from the preventive visit was 1.4 ng/mL, which he was told by phone, and his colonoscopy is booked for next month. He has had no leg or abdominal swelling, black stools, confusion or yellowing. [S]

ElementDetail
Semaglutide1 mg weekly for four months
Home blood pressureAverage 124/78
Weight97.2 kg, down 6.8 kg (6.5%)
AlcoholNone since March
ScreeningPSA 1.4 ng/mL; colonoscopy next month

Review of Systems

SystemResultFinding
GastrointestinalNegativeNo abdominal swelling, black stools or nausea
NeurologicalNegativeNo confusion or sleep reversal
CardiovascularNegativeNo ankle swelling

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for yearsOne tablet twice daily with mealsOral route2008-02-16activeS
Lisinopril 20 mg oral tablet, one tablet daily; taken for yearsOne tablet dailyOral route2008-02-16activeS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route2008-02-16activeS
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2008-03-02 to 2008-04-13completedS
Amlodipine 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2008-04-13activeS
Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly0.25 mg weekly for four weeks, then 0.5 mg weeklySubcutaneous route2008-03-02 to 2008-05-18completedS
Semaglutide pen (1 mg per dose), 1 mg under the skin once weekly1 mg once weeklySubcutaneous route2008-05-18activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2008-09-14Body height182cmS
2008-09-14Body weight97.2kgS
2008-09-14Body mass index (BMI) [Ratio]29.3kg/m2S
2008-09-14Systolic blood pressure122mm[Hg]S
2008-09-14Diastolic blood pressure76mm[Hg]S
2008-09-14Heart rate72/minS
2008-09-14Respiratory rate16/minS
2008-09-14Body temperature36.7CelS
2008-09-14Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2008-09-14Hemoglobin A1c/Hemoglobin.total in Blood6.8%Below 5.7% is normal; goal below 7% for himHighS
2008-09-14Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2008-09-14Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2008-09-14Creatinine [Mass/volume] in Serum or Plasma1.06mg/dL0.74-1.35 mg/dLNormalS
2008-09-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2003)/1.73 sq M78mL/min/{1.73_m2}60 or higher without kidney damage markers is not CKDNormalS
2008-09-14Albumin/Creatinine [Mass Ratio] in Urine14mg/gBelow 30 mg/g is normal (A1)NormalS
2008-09-14Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma38U/L10-40 U/LNormalS
2008-09-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-55 U/LNormalS
2008-09-14Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2008-09-14Bilirubin.total [Mass/volume] in Serum or Plasma0.8mg/dL0.1-1.2 mg/dLNormalS
2008-09-14Platelets [#/volume] in Blood by Automated count14010*3/uL150-400 10*3/uLLowS
2008-09-14Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma4ng/mL<=8.3 ng/mLNormalS

Physical Exam

Vital signs recorded on 2008-09-14; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 122/76, pulse 72; weight 97.2 kg, BMI 29.3
AbdomenSoft; no ascites
SkinNo jaundice
NeurologicalNo asterixis

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetesactiveconfirmed E11.65S — Synthetic modern diagnosis; diabetes was reported publicly during his life, but its duration and treatment here are synthetic.
Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressureactiveconfirmed I10S — Synthetic modern diagnosis; high blood pressure was reported publicly during his life.
Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluatedresolvedconfirmed R74.01S — Synthetic presenting finding, superseded at the two-week visit by the elastography and ultrasound diagnosis.
Metabolic dysfunction-associated steatotic liver disease (MASLD): steatosis on elastography (controlled attenuation parameter 318 dB/m) and ultrasound, with diabetes, obesity, low HDL and high triglycerides, and little alcoholactiveconfirmed K76.0S — Synthetic modern diagnosis. Not part of the public record of his life; chosen to teach surveillance.
Compensated cirrhosis (compensated advanced chronic liver disease) from MASLD: liver stiffness 17.6 kPa, platelets 138, nodular liver surface and a spleen of 13.4 cm on ultrasound; no ascites, encephalopathy, bleeding or jaundice; Child-Pugh Aactiveconfirmed K74.69S — Synthetic modern diagnosis. Not part of the public record of his life; the liver cancer diagnosed three years later in the true frame does not appear in the modern episode.
Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statinactiveconfirmed E78.5S — Synthetic laboratory finding.
Obesity, class 1 (BMI 31.4)activeconfirmed E66.811S — Synthetic finding; described without stigma.
Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30activeconfirmed H54.62S — Synthetic modern measurement anchored to the documented cataract in his left eye.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingLiver ultrasound with AFP for hepatocellular carcinoma surveillanceEvery 6 months in cirrhosisCompleted todayUltrasound: no focal lesion, no ascites, visualization score A; AFP 4.0 ng/mL; on schedule six months after the baseline
LaboratoryLiver function (albumin, bilirubin, INR, platelets; Child-Pugh and MELD)At diagnosis, then every 6 monthsCompleted todayAlbumin 4.1, bilirubin 0.8, platelets 140; Child-Pugh A
LaboratoryLiver tests with FIB-4Yearly with diabetes; FIB-4 1.3 or higher leads to elastographyCompleted todayAST 38, ALT 31 U/L; FIB-4 3.12
ImagingTransient elastographyWhen FIB-4 is 1.3 or higher; repeat in 1 to 2 yearsDueRepeat at one year
ReferralVariceal screeningEndoscopy when portal hypertension cannot be ruled out; repeat in 2 years if no varices and the liver injury continuesUp to dateNo varices in April; repeat in two years
LaboratoryHemoglobin A1cEvery 3 months until at goal or after a change in treatment, then every 6 monthsCompleted today6.8%, at goal
ExaminationBlood pressure (clinic and home), weight and BMIEvery visitCompleted today122/76 in the clinic; home average 124/78; weight 97.2 kg
LaboratoryPotassium, creatinine and eGFR (CKD-EPI 2003) on lisinoprilEvery 6 months on an ACE inhibitor, and after changesCompleted todaySodium 140, potassium 4.5, creatinine 1.06 mg/dL, eGFR 78
LaboratoryUrine albumin-to-creatinine ratioYearlyCompleted today14 mg/g
ExaminationDilated eye examinationAt the start of care, then every 1 to 2 years; promptly when A1c is falling quickly on a GLP-1 receptor agonistUp to dateDilated examination in June: no diabetic retinopathy
ExaminationComprehensive foot examinationYearlyUp to dateAt intake; next in February
LaboratoryLipid panel4 to 12 weeks after starting a statin, then yearlyUp to dateLDL 68 mg/dL in April; yearly
LaboratoryVitamin B12 on long-term metforminPeriodically on long-term metforminUp to date340 pg/mL at intake
Medication safetyAspirin for primary preventionYearlyNot indicatedBleeding risk with cirrhosis outweighs benefit in primary prevention
Medication safetySemaglutide dose steps, nausea, abdominal pain, gallbladder and pancreatitis symptomsAt each dose stepCompleted today1 mg weekly; no side effects
Self-managementAlcohol abstinenceEvery visitCompleted todayNo alcohol since March
Self-managementWarning signs of decompensation (swelling, confusion, bleeding, jaundice)Every visitCompleted todayReviewed; none
Self-managementVaccines for diabetes and chronic liver diseaseAs dueCompleted todayHepatitis A dose 2, second zoster dose, influenza, COVID-19 and RSV vaccines today

Goal progress:

Immunizations given today: Hepatitis A vaccine, adult, dose 2 of 2; Recombinant zoster vaccine, dose 2 of 2; Influenza vaccine, inactivated, this season; COVID-19 vaccine, mRNA, this season; RSV vaccine, single dose [S]

Guideline basis: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023); AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023); Baveno VII - Renewing consensus in portal hypertension (2022); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026)

Follow-up: Visit in three months. Ultrasound with AFP in six months; hepatology visit with elastography at one year. A1c every six months. Colonoscopy next month. Preventive visit in one year. [S]